Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia
Neuropsychopharmacology Reports · 2024-03 · 44 (1) · 29-33
DOI: 10.1002/npr2.12381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 07.12.2023. Verfasst von Kentaro Kawabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Psychiatry, Ehime University Graduate School of Medicine, Toon City, Japan. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Attention‐deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)‐approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first‐line treatment, with pharmacological treatment added as the second‐line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Child Psychiatry, Ehime University Graduate School of Medicine, Toon City, Japan.
- Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Toon City, Japan.
ORCID-Profile: Kentaro Kawabe
Zitieren
APA
Kawabe, K., Horiuchi, F., Matsumoto, Y., Inoue, S., Okazawa, M., Hosokawa, R., Nakachi, K., Soga, J., & Ueno, S. I. (2024). Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia. Neuropsychopharmacology Reports, 44(1), 29-33. https://doi.org/10.1002/npr2.12381
Vancouver
Kawabe K, Horiuchi F, Matsumoto Y, Inoue S, Okazawa M, Hosokawa R, et al. Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia. Neuropsychopharmacology Reports. 2024;44(1):29-33. doi:10.1002/npr2.12381
BibTeX
@article{Kawabe2024,
author = {Kawabe, Kentaro and Horiuchi, Fumie and Matsumoto, Yu and Inoue, Saori and Okazawa, Maya and Hosokawa, Rie and Nakachi, Kiwamu and Soga, Junya and Ueno, Shu-Ichi},
title = {Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia},
journal = {Neuropsychopharmacology Reports},
year = {2024},
volume = {44},
number = {1},
pages = {29--33},
doi = {10.1002/npr2.12381}
}
EUVIMED